Dare Bioscience Files 8-K Report

Ticker: DARE · Form: 8-K · Filed: Jul 14, 2025 · CIK: 1401914

Sentiment: neutral

Topics: sec-filing, 8-k, corporate-update

TL;DR

Dare Bioscience filed an 8-K, mostly boilerplate with exhibits. Keep an eye out for more details.

AI Summary

On July 14, 2025, Dare Bioscience, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or new material events were detailed in the provided excerpt.

Why It Matters

This filing indicates that Dare Bioscience, Inc. is providing updated information to the SEC, which could include financial details or other material events relevant to investors.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing notification without specific material events or financial disclosures that would immediately impact risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Dare Bioscience, Inc.?

The filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, covering Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported is dated July 14, 2025.

In which state is Dare Bioscience, Inc. incorporated?

Dare Bioscience, Inc. is incorporated in Delaware.

What are the former names of Dare Bioscience, Inc. mentioned in the filing?

The former names mentioned are Cerulean Pharma Inc. and Tempo Pharmaceuticals Inc.

What is the principal executive office address for Dare Bioscience, Inc.?

The principal executive office address is 3655 Nobel Drive, Suite 260, San Diego, CA 92122.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 14, 2025 regarding Dare Bioscience, Inc. (DARE).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing